The pharmaceutical industry is one of the most important sectors in the global economy. It is responsible for the development and production of medicines and treatments that help people live longer and healthier lives. As such, it is no surprise that pharmaceutical ETFs have become increasingly popular in recent years.
In this article, we will take a look at the five biggest pharmaceutical ETFs in 2023. We will discuss their performance, holdings, and fees, as well as their potential for growth in the coming years.
The first ETF on our list is the iShares Nasdaq Biotechnology ETF (IBB). This ETF tracks the performance of the Nasdaq Biotechnology Index, which is composed of companies involved in the research, development, and commercialization of biotechnology products. The ETF has a total of $14.3 billion in assets under management and has returned an average of 11.3% over the past five years.
The second ETF on our list is the SPDR S&P Pharmaceuticals ETF (XPH). This ETF tracks the performance of the S&P Pharmaceuticals Select Industry Index, which is composed of companies involved in the research, development, and commercialization of pharmaceutical products. The ETF has a total of $2.2 billion in assets under management and has returned an average of 8.7% over the past five years.
The third ETF on our list is the VanEck Vectors Pharmaceutical ETF (PPH). This ETF tracks the performance of the MVIS Global Pharmaceuticals Index, which is composed of companies involved in the research, development, and commercialization of pharmaceutical products. The ETF has a total of $1.2 billion in assets under management and has returned an average of 8.2% over the past five years.
The fourth ETF on our list is the First Trust NYSE Arca Biotechnology Index Fund (FBT). This ETF tracks the performance of the NYSE Arca Biotechnology Index, which is composed of companies involved in the research, development, and commercialization of biotechnology products. The ETF has a total of $1.1 billion in assets under management and has returned an average of 8.1% over the past five years.
The fifth ETF on our list is the iShares Global Healthcare ETF (IXJ). This ETF tracks the performance of the S&P Global 1200 Healthcare Index, which is composed of companies involved in the research, development, and commercialization of healthcare products. The ETF has a total of $1.0 billion in assets under management and has returned an average of 7.9% over the past five years.
These five ETFs are some of the biggest and most popular pharmaceutical ETFs in 2023. They all have a solid track record of performance and offer investors exposure to a wide range of pharmaceutical companies. However, it is important to remember that past performance is not indicative of future results. As such, investors should always do their own research before investing in any ETF.
